In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs. The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.
| Meeting Date |
Review Type |
Drug Classes/New Drugs Under Review/Information for Manufacturers |
Meeting Window for Manufacturers to give Clinical/Cost Presentation |
|
February 2015
|
Class Review |
Oral Oncological Agents/Prostate I & II |
December 2014
Belsomra - Solicitation Cancelled
|
| Class Review |
Transmucosal Immediate Rlease Fentanyl |
| Class Review |
Pulmonary Aterial Hypertension Agents |
| Designated Newly Approved Drugs |
Zonitivity, Hetlioz, Belsomra, Jardiance, Esomeprasole Strontium, Stendra |
|
May 2015
|
Class Review |
Newer Oral Anticoagulants and Warfarin |
March 2015 |
| Class Review |
Hepatitis Antivirals (Hepatitis C) |
| Designated Newly Approved Drugs |
Belsomra, Plegridy, Diclegis |
| August 2015 |
Class Review |
Diabetes Non-Insulin (GLP-1 Receptor Agonists) |
June 2015
|
| Class Review |
Diabetes Non-Insulin (SGLT-2 Inhibitors) |
| Class Review |
Narcotic Analgesics - Long Acting |
| Class Review |
Oncological Agents - CML Drugs |
| Designated Newly Approved Drugs |
Incruse Ellipta, Cosentyx |
| November 2015 |
Class Review |
Attention Deficit Hyperactivity Disorder - Stimulants |
October 2015
|
| Class Review |
Antirheumatics - Injectable Methorexate |
| Class Review |
Gastrointestinal-2 Agents - Miscellaneous |
| Class Reveiw |
Acne - Isotretinoids |
| Designated Newly Approved Drugs |
Namenda XR, Namzaric |
Subject to Change Disclaimer
The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.
If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.